Ying Yi

Mrs. Ying Yi


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2026 in Kinases and Phosphatases
Verified
Journal Article
Open access
PDF file
DADaylen Aguilar-Noriega
Daylen Aguilar-Noriega
YYYing Yi
Ying Yi
JMJamilet Miranda
Jamilet Miranda
YGYanelda de los Angeles García
Yanelda de los Angeles García
DVDania Vázquez-Blomquist
Dania Vázquez-Blomquist
SPSilvio E. Perea
Silvio E. Perea
HMGB-1 is an alarmin representative of DAMP playing a central role in immunogenic cell death (ICD), a necessary condition in the dialog established between dying tumor cells and the immune system during some anticancer therapies. Therefore, early screening for ICD inducers represents a major priority in drug development today. In this work, we investigated the effect elicited by the clinical-grade CIGB-300 peptide, which impairs Protein Kinase CK2-mediated phosphorylation and other CK2 signaling connected kinases. Here, HMGB-1 extracellular release was investigated in an 18-cell line panel from blood malignancies, uterine-cervical cancer and NSCLC treated with CIGB-300 at equipotent doses (IC50) over 24 h. Interestingly, CIGB-300 treatment upregulated the HMGB-1 protein levels at the culture supernatant in most of the cell lines (p = 0.01) and fold-change increases ≥ 2 were associated with intrinsic cell line sensitivity towards CIGB-300’s cytotoxic effect. However, the HMGB-1 release by CIGB-300 was context-specific with clear induction on blood and uterine-cervical cancer cells and a diffused response pattern in NSCLC. Importantly, CIGB-300 treatment of blood cancer patients enrolled in a Phase I study induced plasma HMGB-1 alarmin in 4 out of 7 subject who received the entire treatment plan. Altogether, our data reveal for the first time that CIGB-300 treatment is able to induce extracellular HMGB-1 release in vitro and in vivo which could be indicative of ICD induction in some kinds of tumors; furthermore, the induction of extracellular HMGB-1 alarmin as a putative CIGB-300 response biomarker merits further investigation.

2 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
DADaylen Aguilar-Noriega
Daylen Aguilar-Noriega
YYYing Yi
Ying Yi
JMJamilet Miranda
Jamilet Miranda
YGYanelda de los Angeles García
Yanelda de los Angeles García
DVDania Vázquez-Blomquist
Dania Vázquez-Blomquist
SPSilvio E. Perea
Silvio E. Perea
HMGB-1 is an alarmin representative of DAMP playing a central role in the immuno-genic cell death (ICD), a necessary condition in the dialogue stablished between dying tumor cells and immune system during some anticancer therapies. Therefore, early screening for ICD inducers represents a major priority in drug development today. In this work, we investigated the effect elicited by the clinical-grade CIGB-300 peptide, which impairs the Protein Kinase CK2-mediated phosphorylation and other CK2 signaling connected kinases. Here, the HMGB-1 extracellular release was investigated in an 18-cell line panel from blood malignancies, uterine-cervical cancer and NSCLC treated with CIGB-300 at equipotent doses (IC50) during 24 hours. Interestingly, CIGB-300 treatment upregulated the HMGB-1 protein levels at the culture supernatant in most of the cell lines (p=0.01) and fold-change increase ≥2 trended to be associated with intrinsic cell line sen-sitivity towards CIGB-300 cytotoxic effect. However, the HMGB-1 release by CIGB-300 was context-specific with clear induction on blood and uterine-cervical cancer cells and a diffused response pattern in NSCLC. Importantly, CIGB-300 treatment of blood cancer patients enrolled in a Phase I study induced plasma HMGB-1 alarmin in 4 out of 7 subject who received the entire treatment plan. Altogether, our data reveal for the first time that CIGB-300 treatment is able to induce extracellular HMGB-1 release in vitro and in vivo which could be indicative of ICD induction in some kind of tumors, also the induction of extracellular HMGB-1 alarmin as putative CIGB-300 response biomarker merits further investigation.